Correction to "Elucidation of a Novel Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy".

Bryna L Fitzgerald; M Nurul Islam; Barbara Graham; Sebabrata Mahapatra; Kristofor Webb; W Henry Boom; Stephanus T Malherbe; Moses L Joloba; John L Johnson; Jill Winter; Gerhard Walzl; John T Belisle

doi:10.1021/acsinfecdis.9b00068

Publisher Website

Correction to "Elucidation of a Novel Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy".

Authors

Fitzgerald, Bryna L
Islam, M Nurul
Graham, Barbara
Mahapatra, Sebabrata
Webb, Kristofor
Boom, W Henry
Malherbe, Stephanus T
Joloba, Moses L
Johnson, John L
Winter, Jill
Walzl, Gerhard
Belisle, John T

Type

Published Article

Journal

ACS Infectious Diseases

Publisher

American Chemical Society

Publication Date

Jun 14, 2019

Volume

5

Issue

6

Pages

1042–1043

Identifiers

DOI: 10.1021/acsinfecdis.9b00068

PMID: 30864780

Source

Medline

Language

English

License

Unknown

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 12/31/2019 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/30864780

Report this publication

Statistics

Seen <100 times

Correction to “Elucidation of a Novel Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy”

Statistics